Skip to content
Screener

Vir Biotechnology, Inc. VIR Business Segments — Plus: Other segment items

Similar metrics at other companies

Cadence Design Systems logo
CDNSReportable Segment — Other segments items
-$58.09M-246%
Broadridge Financial Solutions logo
BRTotal Reportable Segments — Other segment items
$121.4M+7.5%
Iron Mountain logo
IRMTOTAL REPORTABLE SEGMENTS — Other segment items
$938.34M+13.0%
CNN
CNNETotal Reportable Segments — Other segment items
$17.4M+89.1%
GLW
GLWTotal Reportable Segments — Other segment items
$2.77B+16.4%
RCI Hospitality Holdings logo
RICKReportable Segments Excluding Other — Other segment items
$0-100%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Personnel (2)28,51233,16560,04066,883
Clinical costs22,53220,36148,66640,967
Licenses, collaborations and contingent consideration, net41,21111,30138,40247,892
Other R&D (3)19,06118,61937,12337,013
Selling, general and administrative (2)30,19622,28353,53546,227
Restructuring, long-lived assets impairment and related charges, net(172)(182)
Plus: Other segment items (4)6,6137,45913,20826,041
Segment and consolidated net income (loss)$80,080$(110,958)$(45,615)$(231,923)

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s business segments — plus: other segment items?
Vir Biotechnology, Inc. (VIR) reported business segments — plus: other segment items of $6.61M in Q2 2026.
How has Vir Biotechnology, Inc.'s business segments — plus: other segment items changed year-over-year?
Vir Biotechnology, Inc.'s business segments — plus: other segment items decreased by 11.3% year-over-year, from $7.46M to $6.61M.
What is the long-term trend for Vir Biotechnology, Inc.'s business segments — plus: other segment items?
Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — plus: other segment items has grown at a -49.3% compound annual growth rate (CAGR), from $317.23M to $41.34M.
What does business segments — plus: other segment items mean?
Includes miscellaneous income or expense items specific to the segment that do not fall into standard operating categories. This metric is used to reconcile segment performance by capturing unique financial events or adjustments relevant to the segment's specific operations.

Ask your AI about Vir Biotechnology, Inc.'s business segments — plus: other segment items.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude